All In Biotech

Drug Trial Radar · NCT00486811

A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

A Randomized Double-blind, Placebo- and Active-control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee.

Last checked: Nov 19, 2026Latest source record: Oct 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 990 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

990

Actual

Start

Jun 2007

Primary completion

Jul 2008

Study completion Jul 2008

Sponsor

Lead sponsor
Grünenthal GmbHIndustry
Sponsor type
Industry
Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First posted
Jun 15, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether tapentadol (CG5503) prolonged-release (PR) tablets at doses of 100-250 mg twice daily provide a better pain relief in patients with moderate to severe chronic pain due to osteoarthritis of the knee than a placebo (a medication without active substance). In addition the tolerability of CG5503 PR will be assessed. One third of the patients will receive CG5503 and one third will receive placebo. For further comparison one third of the patients will receive oxycodone controlled release (CR) at doses of 20-50 mg twice daily which is an active approved pain medication. Please note that tapentadol ER (Extended Release) and tapentadol PR (Prolonged Release) are identical and used interchangeably. This is due to United States of America and European naming conventions.

Conditions

  • Pain
  • Knee Osteoarthritis

Interventions

  • Tapentadol ER (100 to 250 mg twice daily)Drug

    50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)

  • Matching Placebo (twice daily)Drug

    Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)

  • Oxycodone CR (20 to 50 mg twice daily)Drug

    10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline of the Average Pain Intensity Overall in the 12-week Maintenance Period of the Daily Pain Intensity on an 11-point Numeric Rating Scale (NRS).Time frame: Change from baseline over the 12 week Maintenance Period

Locations

100 sites in 13 countries. Site status is shown where the registry gives one.

  • Site 043005

    Innsbruck, Austria

  • Site 043006

    Mitterdorf, Austria

  • Site 043002

    Salzburg, Austria

  • Site 043001

    Vienna, Austria

  • Site 043004

    Vienna, Austria

  • Site 043003

    Wiener Neustadt, Austria

  • Site 385003

    Karlovac, Croatia

  • Site 385001

    Osijek, Croatia

  • Site 385004

    Sisak, Croatia

  • Seite 385005

    Zagreb, Croatia

  • Site 385002

    Zagreb, Croatia

  • Site 049002

    Berlin, Germany

  • Site 049008

    Berlin, Germany

  • Site 049010

    Berlin, Germany

  • Site 049003

    Dresden, Germany

  • Site 049004

    Frankfurt, Germany

  • Site 049007

    Hamburg, Germany

  • Site 049001

    Leipzig, Germany

  • Site 049005

    Magdeburg, Germany

  • Site 049009

    Schwerin, Germany

  • Site 049006

    Wiesbaden, Germany

  • Site 036003

    Budapest, Hungary

  • Site 036005

    Budapest, Hungary

  • Site 036006

    Budapest, Hungary

  • Site 036009

    Budapest, Hungary

  • Site 036008

    Debrecen, Hungary

  • Site 036004

    Kecskemét, Hungary

  • Site 036007

    Kecskemét, Hungary

  • Site 036002

    Visegrád, Hungary

  • Site 039002

    Chieti, Italy

  • Site 039003

    Milan, Italy

  • Site 039004

    Pavia, Italy

  • Site 039001

    Perugia, Italy

  • Site 371002

    Bauska, Latvia

  • Site 371004

    Riga, Latvia

  • Site 371005

    Riga, Latvia

  • Site 031008

    Eindhoven, Netherlands

  • Site 031003

    Losser, Netherlands

  • Site 031006

    Oude Pekela, Netherlands

  • Site 031004

    s'Hertogenbosch, Netherlands

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.